company background image
TLT logo

Theralase Technologies TSXV:TLT Stock Report

Last Price

CA$0.18

Market Cap

CA$44.9m

7D

5.9%

1Y

-25.0%

Updated

03 Oct, 2024

Data

Company Financials +

Theralase Technologies Inc.

TSXV:TLT Stock Report

Market Cap: CA$44.9m

TLT Stock Overview

A clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.

TLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Theralase Technologies Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theralase Technologies
Historical stock prices
Current Share PriceCA$0.18
52 Week HighCA$0.28
52 Week LowCA$0.14
Beta1.36
11 Month Change2.86%
3 Month Change-5.26%
1 Year Change-25.00%
33 Year Change-12.20%
5 Year Change-16.28%
Change since IPO-80.65%

Recent News & Updates

Recent updates

Is Theralase Technologies (CVE:TLT) In A Good Position To Deliver On Growth Plans?

Jul 29
Is Theralase Technologies (CVE:TLT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Theralase Technologies' (CVE:TLT) Cash Burn Rate

Apr 08
We're Not Very Worried About Theralase Technologies' (CVE:TLT) Cash Burn Rate

Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Dec 24
Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Sep 03
Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Shareholder Returns

TLTCA Medical EquipmentCA Market
7D5.9%1.5%0.4%
1Y-25.0%-7.5%24.6%

Return vs Industry: TLT underperformed the Canadian Medical Equipment industry which returned -7.5% over the past year.

Return vs Market: TLT underperformed the Canadian Market which returned 24.6% over the past year.

Price Volatility

Is TLT's price volatile compared to industry and market?
TLT volatility
TLT Average Weekly Movement10.3%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.3%
10% most volatile stocks in CA Market17.1%
10% least volatile stocks in CA Market3.0%

Stable Share Price: TLT has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: TLT's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aRoger Dumoulin-Whitewww.theralase.com

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.

Theralase Technologies Inc. Fundamentals Summary

How do Theralase Technologies's earnings and revenue compare to its market cap?
TLT fundamental statistics
Market capCA$44.92m
Earnings (TTM)-CA$4.41m
Revenue (TTM)CA$920.62k

47.5x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLT income statement (TTM)
RevenueCA$920.62k
Cost of RevenueCA$469.55k
Gross ProfitCA$451.07k
Other ExpensesCA$4.86m
Earnings-CA$4.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.018
Gross Margin49.00%
Net Profit Margin-478.72%
Debt/Equity Ratio0%

How did TLT perform over the long term?

See historical performance and comparison